



FONDAZIONE
INTERNAZIONALE
MENARINI

International Workshop on Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates

Como (Italy), October 20-21, 2006

Organized by
DEPARTMENT OF DRUG SCIENCES AND CENTER OF EXCELLENCE ON AGING
G. D'ANNUNZIO UNIVERSITY SCHOOL OF MEDICINE
CHIETI (ITALY)

FONDAZIONE INTERNAZIONALE MENARINI

PRELIMINARY PROGRAM

Centro di Cultura Scientifica
"ALESSANDRO VOLTA"
Villa Olmo
Como-Italy

=====
The anthracyclines enjoy a longer than 40 years record of longevity and still play an undisputed key role in the treatment of breast cancer and many other tumors. Unfortunately however, anthracyclines will also induce cardiomyopathy and congestive heart failure often refractory to common medications, and combining anthracyclines with new generation chemotherapeutics or targeted therapies may further aggravate cardiotoxicity. The molecular and clinical aspects of anthracycline cardiotoxicity therefore pose a number of questions that only in part have been answered: why is the heart so vulnerable and what can be done to protect it while leaving the tumors exposed to anthracyclines? what can be done to identify patients carrying an increased risk to develop cardiotoxicity? what kind of synergism links the old anthracyclines to the new anticancer agents? and finally, do we have a better anthracycline?

The Menarini Foundation wishes to contribute to this debate by hosting an “International Workshop on Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates”, organized by Prof. Giorgio Minotti (University of Chieti, Italy) and co-chaired by Dr. Narine Sarvazyan (The George Washington University, Washington DC). This Workshop is aimed at fostering interactions between preclinical and clinical investigators with interest in the molecular mechanisms, pathophysiology and clinical readouts of cardiotoxicity induced by anthracyclines, whether administered as single agents or in combination with other chemotherapeutics.

The Scientific Program is structured as a full circle from Clinical Aspects (session I) to Molecular Mechanisms (session II) and Cardioprotection (session III). Each session will be followed by a plenary Forum that will serve an opportunity to exchange ideas and challenge concepts and research directions. Hopefully, this approach will form the basis to incorporate the viewpoints of clinicians and preclinical investigators in a comprehensive and productive framework.

The Workshop will take place October 20-21, 2006, at Villa Olmo, a beautiful neoclassic venue on the Lake of Como. Villa Olmo is home of a scientific center dedicated to Alessandro Volta (1745-1827), a pioneer in the field of electricity and inventor of the battery. We trust that the spiritual patronage of Alessandro Volta will “electrify” all attendees and will offer resuscitating “voltages” to improve the molecular understanding and clinical handling of anthracycline cardiotoxicity.

We have the pleasure to announce the organization of this Workshop and warmly invite you to attend it in a scenical and historical environment.

*Giorgio Minotti
and Narine Sarvazyan
Co-Chairs*

=====

President of the Workshop

Giorgio Minotti

Professor of Pharmacology
G. d'Annunzio University School of Medicine
Chieti (Italy)

Co-Chair

Narine Sarvazyan

Associate Professor
Department of Pharmacology and Physiology
The George Washington University
Washington (USA)

Scientific secretaries

Emanuela Salvatorelli and Pierantonio Menna
Department of Drug Sciences and Center of Excellence on Aging
G. d'Annunzio University School of Medicine
Chieti (Italy)

esalvatorelli@unich.it

pmenna@unich.it

Organizing secretariat

Fondazione Internazionale Menarini
Piazza del Carmine, 4-I-20121 MILAN (Italy)
Phone: +39 02 874932 / 866715
Fax: +39 02 804739
E-mail: milan@fondazione-menarini.it
Http: [\\www.fondazione-menarini.it](http://www.fondazione-menarini.it)

Friday, October 20th, 2006 – h. 9.00
Villa Olmo (Como)

09.00-09.10 *Foreword:* **G. Minotti** (Chieti, I)

SESSION I - Clinical Aspects

Chairmen: **L. Gianni** (Milan, I)
S. Lipshultz (Miami, USA)
P. Suter (Bern, CH)

09.10-09.30 **H. Cortes-Funes** (Madrid, E)
Anthracyclines in the era of targeted Therapy

09.30-09.50 **P. Suter** (Bern, CH)
Drug Induced cardiomyopathy: Pathophysiology and diagnosis

09.50-10.10 **P. Valagussa** (Milan, I)
Anthracycline cardiotoxicity in breast cancer patients: Prospective and retrospective analysis of risk factors

10.10-10.30 **L. Wojnowski** (Mainz, D)
Genotyping the risk of doxorubicin cardiotoxicity

10.30-10.50 Coffee Break

10.50-11.10 **L. Gianni** (Milan, I)
Anthracycline cardiotoxicity in breast cancer patients: Synergism with taxanes and trastuzumab

11.10-11.30 **G. Batist** (Montreal, CDN)
Cardiac safety of liposomal anthracyclines

11.30-11.50 **C. Sessa** (Bellinzona, CH)
Ongoing Phase I and II studies of novel anthracyclines

11.50-12.20 Discussion Leaders
G. Batist(Montreal, CDN)
P. Valagussa (Milan, I)
Is cardiotoxicity still a clinical problem?

Friday, October 20th, 2006 – h. 15.00
Villa Olmo (Como)

SESSION II -Molecular Mechanisms

- Chairs:** **G. Minotti** (Chieti, I)
 N. Sarvazyan (Washington, USA)
- 15.00-15.10 **G. Minotti** (Chieti, I)
 Metabolic determinants of the iron and oxyradical hypotheses of cardiotoxicity
- 15.10-15.30 **J. Robert** (Bordeaux-Cedex, F)
 Experimental models of acute and chronic cardiotoxicity
- 15.30-15.50 **B. Kalyanaraman** (Milwaukee, USA)
 Iron signalling and oxidant damage
- 15.50-16.10 **K. Wallace** (Duluth, USA)
 Anthracycline mitochondrionopathy
- 16.10-16.30 **J.Y. Kang** (Louisville, USA)
 Antioxidant defenses: lessons from transgenic animals and proteomics
- 16.30-16.50 Coffee Break
- 16.50-17.10 **U. Walker** (Freiburg, D)
 Anthracyclines and mtDNA lesions
- 17.10-17.30 **N. Sarvazyan** (Washington, USA)
 Anthracyclines and phospholipases
- 17.30-17.50 **D.B. Sawyer** (Boston, USA)
 Anthracyclines and the cytoskeleton
- 17.50 18.20 Discussion Leaders
 G. Cairo (Milan, I)
 J.Y. Kang (Louisville, USA)
 Controversies on the role of iron and oxyradicals

Saturday, October 21st, 2006 – h. 09.00
Villa Olmo (Como)

SESSION III - Cardioprotection

Chairs: **B. Hasinoff** (Winnipeg, CDN)
E. Herman (Silver Spring, USA)

- 09.00-09.20 **B. Hasinoff** (Winnipeg, CDN)
Dexrazoxane: how it works in cardiac and tumor cells
- 09.20-09.40 **M. Sehested** (Copenahgen, DK)
New analogs and applications of dexrazoxane
- 09.40-10.00 **S. Lipshultz** (Miami, USA)
Clinical experience with dexrazoxane
- 10.00-10.20 **H. Kaiserova** (Hradec Kralove, CZ)
New iron chelators in doxorubicin-induced cardiotoxicity
- 10.20-10.40 Coffee Break
- 10.40-11.00 **A. Bast** (Maastricht, NL)
Flavonoids, from chemistry to clinical trials
- 11.00-11.20 **K. Hideg** (Pecs, H)
Novel antioxidants in anthracycline cardiotoxicity
- 11.20-11.50 Discussion Leaders
A. Bast (Maastricht, NL)
S. Lipshultz (Miami, USA)
Risk: benefit ratio of cardioprotectants
- 11.50-12.10 **N. Sarvazyan** (Washington, USA)
Closing of the Meeting